Mechanisms, Resistance and Biofilm in Orthopaedics
- Antibiotics are grouped by their TARGET: CELL-WALL synthesis (BETA-LACTAMS - penicillins/cephalosporins/carbapenems inhibit penicillin-binding proteins; GLYCOPEPTIDES like vancomycin bind D-ala-D-ala); PROTEIN synthesis at the ribosome (AMINOGLYCOSIDES, MACROLIDES, CLINDAMYCIN, LINEZOLID, TETRACYCLINES); DNA/RNA (FLUOROQUINOLONES inhibit DNA gyrase, RIFAMPICIN inhibits RNA polymerase, metronidazole); and FOLATE synthesis (trimethoprim-sulfamethoxazole).
- Antibiotics are BACTERICIDAL (kill, e.g. beta-lactams, glycopeptides, aminoglycosides, fluoroquinolones, rifampicin) or BACTERIOSTATIC (inhibit growth, e.g. tetracyclines, macrolides, clindamycin, linezolid); killing is either CONCENTRATION-DEPENDENT (aminoglycosides, fluoroquinolones - high peak matters) or TIME-DEPENDENT (beta-lactams, glycopeptides - time above MIC matters), which guides dosing.
- RESISTANCE arises by four mechanisms: (1) ENZYMATIC INACTIVATION (beta-lactamases, including ESBL and carbapenemases), (2) TARGET MODIFICATION (altered penicillin-binding protein PBP2a in MRSA via mecA; altered D-ala-D-lac in VRE via vanA; gyrase/ribosomal mutations), (3) REDUCED UPTAKE/decreased permeability (porin loss) and (4) EFFLUX PUMPS; resistance genes spread by plasmids/transposons (horizontal gene transfer), producing MRSA, VRE, ESBL and multidrug-resistant gram-negatives.
- BIOFILM is the key orthopaedic concept: bacteria on an implant or dead bone form a structured community embedded in a self-produced extracellular matrix (glycocalyx), which confers antibiotic TOLERANCE (distinct from genetic resistance) through REDUCED antibiotic PENETRATION, SLOW-GROWING/dormant PERSISTER cells and SMALL-COLONY VARIANTS, and an altered microenvironment.
- Because of biofilm tolerance, ANTIBIOTICS ALONE typically FAIL against implant-associated infection (periprosthetic joint infection, implant-related osteomyelitis) - effective treatment requires SURGICAL removal/debridement of the biofilm (and often the implant) PLUS antibiotics; this is why source control is paramount.
- RIFAMPICIN is special: it penetrates the STAPHYLOCOCCAL biofilm and intracellular bacteria well, so it is a key agent for staphylococcal implant infection - but it must ALWAYS be used in COMBINATION (never as monotherapy) because resistance to rifampicin develops rapidly; fluoroquinolones (good bone penetration) are common rifampicin partners for susceptible gram-negative/staph PJI.
- “Targets: cell wall (beta-lactams, vancomycin), ribosome (aminoglycosides/macrolides/clindamycin/linezolid/tetracyclines), DNA/RNA (fluoroquinolones, rifampicin), folate (TMP-SMX).
- “Resistance: enzyme (beta-lactamase), target modification (MRSA PBP2a/mecA, VRE vanA), efflux, reduced uptake; spread by plasmids.
- “Biofilm = TOLERANCE (not resistance): reduced penetration + persisters/small-colony variants -> antibiotics alone fail -> need SURGERY + antibiotics. Rifampicin penetrates staph biofilm (ALWAYS combination).
Bacteria in an extracellular matrix on the implant: reduced antibiotic penetration + persister cells / small-colony variants -> antibiotics alone fail (tolerance, not classic resistance).
Surgical debridement / implant removal (source control) plus antibiotics; rifampicin for staphylococcal biofilm (always in combination).
Antibiotic Classes & Mechanisms
Antibiotics work on four main bacterial targets. Cell-wall synthesis is inhibited by beta-lactams (penicillins, cephalosporins, carbapenems - which block penicillin-binding proteins/transpeptidase) and glycopeptides (vancomycin, teicoplanin - which bind the D-ala-D-ala terminus; key for gram-positives and MRSA). Protein synthesis at the ribosome is inhibited by aminoglycosides (gentamicin - 30S, bactericidal, used in cement/beads), macrolides, clindamycin, linezolid (for MRSA/VRE) and tetracyclines. DNA/RNA is targeted by fluoroquinolones (DNA gyrase - good bone penetration, oral), rifampicin (RNA polymerase - excellent biofilm/intracellular penetration) and metronidazole (anaerobes). Folate synthesis is inhibited by trimethoprim-sulfamethoxazole. Drugs are also classed as bactericidal or bacteriostatic, and as concentration-dependent (aminoglycosides/fluoroquinolones) or time-dependent (beta-lactams/glycopeptides) killers - which determines dosing.
Resistance Mechanisms
Bacteria resist antibiotics by four mechanisms:
- Enzymatic inactivation: beta-lactamases (penicillinases, extended-spectrum beta-lactamases/ESBL, carbapenemases) and aminoglycoside-modifying enzymes destroy the drug.
- Target modification: an altered penicillin-binding protein (PBP2a, encoded by mecA) in MRSA; altered cell-wall precursor (D-ala-D-lac via vanA) in VRE; mutated DNA gyrase (fluoroquinolone resistance) or ribosome.
- Reduced uptake / decreased permeability: loss of outer-membrane porins (gram-negatives).
- Efflux pumps: actively pump the drug out. Resistance genes spread by plasmids/transposons (horizontal gene transfer), producing MRSA, VRE, ESBL and multidrug-resistant gram-negatives - relevant to surgical prophylaxis and the empirical treatment of infection.
Biofilm: The Orthopaedic Key
A biofilm is a structured community of bacteria adherent to a surface (implant, dead bone/sequestrum) within a self-produced extracellular matrix (glycocalyx). It causes antibiotic TOLERANCE - a phenotypic, reversible survival distinct from genetic resistance - through reduced antibiotic penetration into the matrix, slow-growing/dormant PERSISTER cells and SMALL-COLONY VARIANTS that survive antibiotic exposure, and an altered local microenvironment. This is why antibiotics alone fail to clear implant-associated infection and why SURGICAL source control - debridement and often implant removal - is essential, combined with antibiotics. RIFAMPICIN penetrates the staphylococcal biofilm and intracellular bacteria, making it a key agent for staphylococcal implant infection, but it must always be given in COMBINATION (commonly with a fluoroquinolone) because rifampicin monotherapy rapidly selects resistance.
Two cardinal rules in implant infection: first, rifampicin is never used as monotherapy - resistance emerges rapidly, so it is always combined with another biofilm-relevant agent (e.g. a fluoroquinolone for susceptible organisms); and second, antibiotics cannot 'sterilise' a mature biofilm on a foreign body - durable cure needs surgical debridement and (usually) implant removal/exchange alongside antibiotics. Suppressive antibiotics may control, but rarely eradicate, biofilm infection when the implant is retained. Choose agents with good bone penetration (e.g. fluoroquinolones, clindamycin) and use local delivery (gentamicin/vancomycin cement/beads) as an adjunct.
Evidence & Key Studies
Biofilm-mediated antibiotic tolerance precedes resistance in Staphylococcus aureus under antibiotic selection
- In periprosthetic joint infection, bacteria survive antibiotics through biofilm-mediated TOLERANCE, resistance and persistence - antibiotics in isolation are typically ineffective.
- Rifampicin penetrates the S. aureus biofilm whereas vancomycin penetrates poorly; tolerant small-colony variants emerge under antibiotic selective pressure.
- Biofilm-mediated tolerance explains why treatments relying on antibiotics to clear residual biofilm fail - reinforcing the need for surgical source control.
Antimicrobial efficacy differs between planktonic and biofilm bacterial phenotypes (levofloxacin, rifampin)
- Antibiotics have markedly different efficacy against bacteria in the planktonic versus the biofilm phenotype (higher minimum bactericidal concentrations against biofilm).
- Levofloxacin and rifampin were studied against S. aureus biofilm on an implant model, underscoring biofilm tolerance.
- The bacterial phenotype (biofilm) is a key determinant of treatment efficacy for implant infections.
According to PubMed, the central role of biofilm-mediated tolerance (with persister cells/small-colony variants) in periprosthetic joint infection, and rifampicin's biofilm penetration versus vancomycin's poor penetration, come from the cited Manasherob study, and the planktonic-versus-biofilm efficacy difference from the cited Ong study. The antibiotic-class mechanisms, bactericidal/bacteriostatic and concentration-/time- dependent killing, and the four resistance mechanisms (including MRSA mecA and VRE vanA) are standard, well-established pharmacology. (See also our Periprosthetic Joint Infection, Osteomyelitis, Local Antibiotic Delivery and Septic Arthritis topics.)
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“Classify antibiotics by mechanism, and explain the main mechanisms of bacterial resistance.”
“What is biofilm, and why does it mean an infected implant usually cannot be cured by antibiotics alone?”
Mnemonics & Memory Aids
WRDF (targets)
Hook:Antibiotic targets = Wall, Ribosome, DNA/RNA, Folate (WRDF).
BIOFILM
Hook:BIOFILM = tolerance; treat with surgery + biofilm-active antibiotics.
Classes by target
- Cell wall: beta-lactams (PBPs), glycopeptides (vancomycin - D-ala-D-ala)
- Ribosome: aminoglycosides, macrolides, clindamycin, linezolid, tetracyclines
- DNA/RNA: fluoroquinolones (gyrase), rifampicin (RNA pol), metronidazole; folate: TMP-SMX
Killing
- Bactericidal (beta-lactams, glycopeptides, aminoglycosides, fluoroquinolones, rifampicin) vs bacteriostatic
- Concentration-dependent (aminoglycosides, fluoroquinolones)
- Time-dependent (beta-lactams, glycopeptides)
Resistance
- Enzymatic (beta-lactamases/ESBL/carbapenemases)
- Target modification (MRSA mecA/PBP2a; VRE vanA; gyrase mutation)
- Reduced uptake (porin loss); efflux pumps; spread by plasmids
Biofilm (orthopaedic key)
- Matrix on implant -> tolerance (reduced penetration, persisters, small-colony variants)
- Antibiotics alone FAIL -> surgical debridement/implant removal + antibiotics
- Rifampicin penetrates staph biofilm (ALWAYS combination); use bone-penetrating agents + local delivery